Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07074353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Study acronym: CinClare-2
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This study enrolled patients with locally advanced rectal cancer. The experimental group received irinotecan liposomes combined with standard total neoadjuvant therapy (TNT), while the control group received standard TNT. The study endpoints were the complete response rate (cCR + pCR), 3-year event-free survival (EFS) rate, and overall survival (OS). The aim was to compare the efficacy and safety of irinotecan liposomes combined with or without standard TNT.
Trial Details
NCT Number NCT07074353
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 Locally Advanced Rectal Cancer
Enrollment 360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov